Washington, D.C. 20549







Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 5, 2020



Alector, Inc.

(Exact name of registrant as specified in its charter)




Delaware   001-38792   82-2933343

(State or other jurisdiction

of incorporation)



File Number)

  (IRS Employer
Identification No.)

131 Oyster Point Blvd. Suite 600

South San Francisco, California 94080

(Address of principal executive offices, including zip code)

(415) 231-5660

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common Stock    ALEC    The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒




Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Compensatory Arrangements of Certain Officers

On March 5, 2020, the Compensation Committee of the Board of Directors (the “Board”) of the Company approved annual base salaries, effective March 1, 2020, and target cash incentive compensation plan percentages for 2020 (reflected as a percentage of base salary) for the following principal executive officer, principal financial officer and other named executive officers of the Company:


Name and Current Position

     Increase ($)      2020 Base
     2020 Target
Cash Incentive

Arnon Rosenthal, Ph.D.

Chief Executive Officer

   $  525,000      $  35,000      $  560,000      55%

Calvin Yu

Vice President, Finance

   $ 260,600      $ 39,400      $ 300,000      30%

Robert Paul, M.D.

Chief Medical Officer

   $ 392,100      $ 47,900      $ 440,000      40%

Robert King, Ph.D.

Chief Development Officer

   $ 362,500      $ 62,500      $ 425,000      40%

A description of our cash executive incentive compensation plan can be found under the section titled “Executive Compensation” in our prospectus relating to our recent public offering of common stock filed with the SEC on January 30, 2020 pursuant to Rule 424(b) of the Securities Act of 1933, as amended.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




Date: March 9, 2020   By:  

/s/ Shehnaaz Suliman


Shehnaaz Suliman


President and Chief Operating Officer